PharmTech Drug Digest 11.20
|Articles|October 3, 2014

Product Suitability for Intended End Use

This podcast will review BioSpectra?s interpretation of product suitability for intended end use. We will go over the meaning of product suitability as well as provide types of end use applications supported by BioSpectra?s products. Additionally, we will provide examples of BioSpectra?s offerings and key differences of these offerings based on intended end use.

 

This podcast will review BioSpectra’s interpretation of product suitability for intended end use. We will go over the meaning of product suitability as well as provide types of end use applications supported by BioSpectra’s products. Additionally, we will provide examples of BioSpectra’s offerings and key differences of these offerings based on intended end use.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.